**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 7797**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (14): Pancreatic cancer

Emerging role of the KRAS-PDK1 axis in pancreatic cancer

Ferro S *et al*. KRAS-PDK1 in pancreatic cancer

Riccardo Ferro, Marco Falasca

**Riccardo Ferro, Marco Falasca,** Inositide Signalling Group, Blizard Institute, Barts and The London School of Medicine and Dentistry,Queen Mary University of London, London E1 2AT, United Kingdom

**Author contributions:** Ferro R and Falasca M solely contributed to this paper

**Supported by** Pancreatic Cancer Research Fund

**Correspondence to**: **Marco Falasca**, **Professor,** Inositide Signalling Group, Blizard Institute, Barts and The London School of Medicine and Dentistry,Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom. [m.falasca@qmul.ac.uk](mailto:m.falasca@qmul.ac.uk)

**Telephone:** +44-20-78828243 **Fax:** +44-20-78822186

**Received:** November 29, 2013 **Revised:** March 11, 2014

**Accepted:** March 19, 2014

**Published online:**

**Abstract**

Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it has the grim supremacy in terms of unfavourable survival rates. There have been great advances in survival rates for many types of cancers over the past few decades but hardly any change for pancreatic cancer. Mutations of the Ras oncogene are the most frequent oncogenic alterations in human cancers. The frequency of *KRAS* mutations in pancreatic cancer is around 90%. Given the well-established role of KRAS in cancer it is not surprising that it is one of the most attractive targets for cancer therapy. Nevertheless, during the last thirty years all attempts to target directly KRAS protein have failed. Therefore, it is crucial to identify downstream KRAS effectors in order to develop specific drugs able to counteract activation of this pathway. Among the different signalling pathways activated by oncogenic KRAS, the phosphoinositide 3-Kinase (PI3K) pathway is emerging as one of the most promising KRAS effector. In turn, PI3K activates several parallel pathways making the identification of the precise effectors activated by KRAS more difficult. Recent data identify 3-phosphoinositide-dependent protein kinase 1 (PDK1) as a key tumour-initiating event downstream KRAS interaction with PI3K in pancreatic cancer.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words**: Pancreatic cancer, signal transduction; KRAS; Phosphoinositide 3-kinase, 3-phosphoinositide-dependent protein kinase 1

**Core tip:** Recent evidence suggests that PDK1 is a key oncogenic driver in pancreatic cancer. Furthermore, PDK1 appears to be activated downstream the main pancreatic cancer oncogene *KRAS* that is mutated in nearly all pancreatic adenocarcinomas. This evidence suggests that PDK1 could represent a novel target in the treatment of pancreatic cancer.

FerroR, Falasca M. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Pancreatic cancer is a deadly disease both because it is generally discovered very late but also because it is very resistant to chemotherapy and radiation therapy[[1](#_ENREF_1)]. In addition, pancreatic cancer metastasizes very early and recent data suggest that many patients are likely to harbour metastases at the time of diagnosis[[2](#_ENREF_2)]. The most common form of pancreatic cancer occurs in the exocrine cells of the pancreas[[3](#_ENREF_3)]. These tumours account for over 95% of all pancreatic cancers, and can occur anywhere in the pancreas, although most often they are found in the head of the pancreas. Pancreatic ductal adenocarcinoma (PDAC) is the most common type, representing almost 90% of all exocrine tumours.

PDACs develop from cells lining the ducts that carry the digestive juices into the main pancreatic duct and then on into the duodenum. Like other solid tumours, pancreatic cancer is the result of a multistep process. Its initiation and development involves specific genetic changes enabling growth and survival mechanisms, initiation of a marked desmoplastic reaction and finally tissue invasion and metastasis[[4](#_ENREF_4)]. The signalling pathways regulating tumourigenesis are understandably complex, considering the multiple interactions between the pancreatic cells themselves, the supporting stroma and the immune system[[5](#_ENREF_5)].

A careful molecular and pathological analysis of evolving pancreatic adenocarcinoma has revealed a characteristic pattern of histological defined precursors, pancreatic intraepithelial neoplasia (PanIN), that has been excellently modelled by Hruban and colleagues[[6](#_ENREF_6)]. In brief, the morphology of the tumour progresses in steps from normal ducts consisting of normal pancreatic duct cells to aberrant ducts with disorganised cell formations and differentiation grade, and finally to infiltrating cancer. These morphological changes occur along with several genetic lesions. A comprehensive genome analysis of 24 human pancreatic cancers revealed an average of 63 genetic alterations[[7](#_ENREF_7)]. These alterations, mainly point mutations, affect distinct cellular pathways that can be classified in 12 distinct signalling pathways or processes: apoptosis, control of G1/S phase transition, Hedgehog signalling, KRAS signalling, TGF-beta signalling, Wnt/Notch signalling, DNA damage control, homophilic cell adhesion, Integrin signalling, JNK signalling, Invasion and small GTPase signalling (other than KRAS). The first six of these core pathways/processes were found to be genetically altered in all the analysed samples and the last six were altered in 16-23 of the 24 samples[[7](#_ENREF_7)]. A recent comprehensive evaluation of the pancreatic cancer genome has revealed a multitude of new mutated genes involved in chromatin modification and genes associated with embryonic regulation of axon guidance[[1](#_ENREF_1)].

The progression from normal duct epithelium to infiltrating PDAC involves a series of genetic alterations in conjunction with morphological changes. Activating *KRAS* mutation and overexpression of ERBB2 occur early in the progression (PanIN-1), inactivation of the cyclin-dependent kinase inhibitor 2A at an intermediate stage (PanIN-2) and inactivation of TP53, SMAD4 and BRCA2 occur at a late stage (PanIN-3)[[1](#_ENREF_1), [7](#_ENREF_7)] .

Activating KRAS mutations are the first genetic changes that are detected in the progression from PanIN-1 to PanIN-3, even though sporadic mutation can be found in histologically normal pancreas and in lesions that show the earliest stages of histological alterations. With disease progression, the prevalence of *KRAS* mutation increases and occurs in over 90% of pancreatic adenocarcinomas [[1](#_ENREF_1), [8-10](#_ENREF_8)]. Understandably, KRAS-dependent pathways represent the main target in strategies attempting to counteract pancreatic cancer progression. In this review we will discuss the evidence that suggest that targeting the phosphoinositide 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1 (PDK1) pathway can be a valid strategy to counteract KRAS signalling in pancreatic cancer.

**KRAS**

The small GTPase KRAS is frequently mutated in human cancers, with mutations occurring in nearly all tumours. Activating *KRAS* mutations involve only certain amino acids which interfere with the GTPase activity. In pancreatic cancer, mutations are essentially seen only at the twelfth position (amino acid 12). Most mutations in pancreatic cancer change a glycine at amino acid 12 to a valine or aspartate (KRASG12V and KRASG12D respectively) and have a well-established role in the initiation and progression of PDAC[[11](#_ENREF_11), [12](#_ENREF_12)]. The *KRAS* mutation result in a constitutively active protein that promotes persistent signalling to downstream effectors[[13](#_ENREF_13)]. In turn, this hyper activated signalling results in enhanced stimulation of proliferative pathways, thus conferring a growth advantage to the cancer cell. Several genetic studies have shown that activating *KRAS* mutations are necessary for the onset of pancreatic cancer[[14](#_ENREF_14)]. An inducible pancreas-specific expression system was used recently to show that KRASG12D expression is also required for tumour maintenance[[15](#_ENREF_15)]. In addition to cancer, *KRAS* mutations have also been identified in benign conditions such as chronic pancreatitis which result in increased risk of developing PDAC[[16](#_ENREF_16)]. KRAS signals *via* a number of downstream effectors, amongst others RAF kinase, PI3K, guanine exchange factors for the small GTPases RAL (RAL-GEFs) and phospholipase Cε. In PDAC the main signalling pathways downstream of KRAS are the PI3K pathway and the mitogen-activated protein kinase (MAPK) cascade. Studies in pancreatic duct epithelial cell systems have demonstrated that the transforming potential of oncogenic *KRAS* is dependent on PI3K signalling and mutated KRAS is associated with up-regulation of survival signals including the PI3K/Akt survival pathway[[17](#_ENREF_17)]. Knock-down of KRAS in pancreatic cancer cells demonstrated reduced activation of several proteins including Akt and ERK, indicating a key role for KRAS in regulation of the PI3K signalling pathway and the MAPK cascade. Members of the MAPK signalling pathway are rarely genetically modified in pancreatic cancer but this signalling pathway can be hyperactivated by constitutively active KRAS. Indeed targeting the RAF/MEK/ERK pathway in the MAPK cascade with selective drugs has shown promising effects on pancreatic cancer growth. The MAPK cascade and the PI3K pathway are both classically activated *via* Receptor Tyrosine Kinases like the epidermal growth factor receptors (EGFR). Since EGFR gene (*ERBB2*) amplification is one of the early genetic events in the development of pancreatic neoplasia these pathways can be further activated through EGFR in pancreatic cancer[[18](#_ENREF_18)].

**PI3K PATHWAY**

The PI3K pathway is involved in inhibition of apoptosis and stimulation of cell proliferation and it has been estimated that at least 50% of all cancer types are related to deregulation of this signalling pathway[[19](#_ENREF_19)]. Of the 8 mammalian PI3K isoforms gain of PIK3CA (PI3K/p110α) function by mutation is common in several human cancers[[20](#_ENREF_20), [21](#_ENREF_21)]. On the other hand we have recently shown that the PI3K isoform p110γ is specifically overexpressed in PDAC[[22](#_ENREF_22)]. Upon activation the PI3Ks catalyse the phosphorylation of phosphoinoisitides promoting recruitment of downstream signalling molecules such as Akt and PDK1 to the plasma membrane which in turn induce several physiological functions such as cell growth, cell survival, cell migration, and cell cycle entry[[23](#_ENREF_23)].This activation is negatively regulated by the tumour suppressor phosphatase and tensin homolog (PTEN)[[24](#_ENREF_24)]. PTEN mutations are rare in human PDAC, but loss of PTEN function has been shown to be involved in pancreatic cancer resulting in sustained PI3K activation[[25](#_ENREF_25)]. Furthermore, animal models with KRASG12D activation and PTEN deletion develop pancreatic cancer with an accelerated phenotype of acinar-to-ductal metaplasia, leading to PanIN and cancer progression[[26](#_ENREF_26)].

Increased activation of the PI3K effector Akt has shown to be a common feature and a biological indicator of aggressiveness in PDAC[[27](#_ENREF_27), [28](#_ENREF_28)]. Additionally, it has been reported that Akt is a regulator of cell plasticity in the pancreas. Indeed it has shown that constitutively active Akt induced expansion of the ductal compartment, and also led to premalignant lesions *in vivo*[[29](#_ENREF_29)].

PI3K signalling in the microenvironment has further been demonstrated to enhance tumour progression. Specifically, blocking PI3K/p110γ expressed by myeloid cells in the stroma significantly suppresses tumour growth and invasion[[30](#_ENREF_30)].

**KRAS/PI3K/PDK1 AXIS**

It has been recently shown that PDK1 is required for anchorage-independent and xenograft growth of breast cancer cells harbouring either *PI3KCA* or *KRAS* mutations[[31](#_ENREF_31)]. The most compelling evidence for the existence of a KRAS/PI3K/PDK1 axis derives from a recent study demonstrating that PI3K-PDK1 signalling is an essential node of non-oncogene addiction in KRAS-driven pancreatic cancer initiation and maintenance[[32](#_ENREF_32)].

Indeed, using genetic and pharmacological approaches KRAS-PI3K-PDK1 axis has been shown to be an essential pathway for pancreatic cancer being capable to induce cell plasticity, acinar-to-ductal metaplasia, intraepithelial neoplasia, and pancreatic cancer formation as well as tumour maintenance.

Interestingly, the authors further showed that ablation of PDK1 specifically in the epithelial compartment of the lung using two different recombination strategies had no significant inhibitory effect on KRASG12D-induced Non-small-cell lung carcinoma (NSCLC) development and progression, supporting the conclusion that PDK1 might have a specific role downstream of KRAS in pancreatic cancer. Nevertheless, more evidence is required to conclude that PDK1 has a specific role downstream of KRAS in pancreatic cancer.

On the other hand, this demonstrates that there are substantial tissue- and context-specific differences in activation of KRAS effectors. Such differences may have important clinical implications because they could explain the diverse response to targeted therapies of different tumour types harbouring oncogenic KRAS mutations. Indeed, a recent study showed no substantial response of KRASG12D-driven NSCLC toward PI3K-mTOR inhibition *in vivo*[[33](#_ENREF_33)]. We have recently shown that the PDK1-specific inhibitor 2-*O*-benzyl-*myo*-inositol 1,3,4,5,6-pentakisphosphate (2-*O*-Bn-IP5), strongly reduced the number of surviving pancreatic cancer cells *in vitro*[[34](#_ENREF_34)]. Our data further reveal that 2-*O*-Bn-IP5 is able to sensitise cancer cells, including pancreatic cancer cells, to the pro-apoptotic effect of anti-cancer drugs. Our data thus provide further evidence for the rationale to investigate KRAS-driven oncogenic pathways in a tissue- and context-specific manner to characterize the relevant nodes engaged in different tumour entities.

Interestingly, recent work has revealed that PDK1 directly phosphorylates the Polo-like kinase 1 (PLK1) which in turn induces MYC phosphorylation[[35](#_ENREF_35)]. This novel PDK1-PLK1-MYC signalling regulates cancer cell growth and survival. In addition, it has been shown that MYC controls generation of self-renewing metastatic pancreatic cancer cells[36]. Indeed stable expression of activated KRASG12D confers a large degree of phenotypic plasticity to cells that predisposes them to neoplastic transformation and acquisition of stem cell characteristics. Ishenko *et al*. demonstrated that metastatic conversion of KRASG12D-expressing cells, that exhibit different degrees of differentiation and malignancy, can be reconstructed in cell culture, and that the proto-oncogene c-MYC controls the generation of self-renewing metastatic cancer cells[[36](#_ENREF_36)]. These results provide evidence that the conversion of precancerous to cancerous cells is determined by oncogenic RAS-induced transcription factors, primarily MYC. In addition, a cooperative mechanism between mutant *KRAS* and *PIK3CA* has been recently shown, in part mediated by RAS/p110α binding, as inactivating point mutations within the RAS-binding domain of PIK3CA significantly ablates pathway signalling[[37](#_ENREF_37)]. Indeed somatic cell knock-in of both KRASG12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the PI3K and MAPK pathways in vitro, and leads to tumour formation in immunocompromised mice. Xenografts from double knock-in cells retain single copies of mutant *KRAS* and *PIK3CA*, suggesting that tumour formation does not require increased copy number of either oncogene. More importantly PDK1 seems to play a key role in this cooperativity, since PDK1-dependent activation of the downstream effector p90RSK is increased by the combined presence of mutant KRAS and PIK3CA. Finally, PDK1 has been recently found significantly overexpressed in the high-grade intraductal papillary mucinous neoplasms (IPMN) versus low-grade IPMN and in pancreatic and intestinal-type of IPMN versus gastric-type of IPMN[[38](#_ENREF_38)]. These data suggest that PDK1 may play a role in development of IPMN invasive cancer.

**MIR-375, AN ADDITIONAL LINK BETWEEN KRAS AND PDK1**

MicroRNAs (miRNAs) modulate the expression levels of mRNAs and proteins and can contribute to cancer initiation and progression[[39](#_ENREF_39)]. In addition to their intracellular function, miRNAs are released from cells and shed into the circulation. Increasing interest has been recently focused on the role of miRNAs in pancreatic cancer malignant progression[[40](#_ENREF_40)]. It has been reported that changes in miRNAs expression patterns during progression of normal tissues to invasive pancreatic adenocarcinoma in the p48-Cre/LSL-KRASG12D mouse model mirrors the miRNAs changes observed in human pancreatic cancer tissues[[41](#_ENREF_41)]. It was found that the expressions of miR-148a/b and miR-375 were decreased whereas the levels of miR-10, miR-21, miR-100 and miR-155 were increased in invasive carcinoma compared to normal tissues in the mouse model. Similar data has been found in KRAS oncogene transgenic rats with pancreatic ductal adenocarcinomas[[42](#_ENREF_42)]. Recently, miR-375 has been found downregulated in different cancers including pancreatic cancer, and suppresses key cancer functions by targeting several signalling molecules such as PDK1[[43](#_ENREF_42)]. It is worth to note that RAS can up-regulate PDK1 expression. Indeed, it has been shown that RAS drives monocytic lineage commitment in granulomonocytic bipotential cells by promoting the expression of PDK1[[44](#_ENREF_43)].Interestingly, a recent study investigated the transcriptional regulation of miR-375 validated target PDK1[[45](#_ENREF_44)] in pancreatic carcinoma[[46](#_ENREF_45)]. miR-375 was observed to be downregulated in the tumour compared with non-tumour tissues from patients with pancreatic cancer[[41](#_ENREF_41)]. As determined by a luciferase reporter assay, the ectopic expression of miR-375 was able to reduce the transcriptional activity of PDK1 and the expression of endogenous PDK1 protein levels. Functional assays showed that miR-375 was able to inhibit proliferation and promote apoptosis of ~~the~~ pancreatic cancer cells[[46](#_ENREF_45)]. Therefore, miRNA-375 appears to be a key regulator of PDK1, suggesting that it may have a potential therapeutic role in the treatment of pancreatic cancer. Furthermore, this evidence suggests that miR-375 may represent an additional link between KRAS and PDK1 since KRAS-induced downregulation of miR-375 results in increased PDK1 expression.

**CONCLUSION**

This review provides evidence for a role of the KRAS-PDK1 axis in pancreatic cancer. Given the fact that KRAS is considered an “undruggable” protein the identification of downstream targets is of value for the future development of alternative pharmacological strategies to block KRAS-dependent signalling pathways. Highly selective PDK1 inhibitors are now available and combination strategies may achieve more effective blockade of this axis. At AACR 2012, a study demonstrated that nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumour growth[[47](#_ENREF_45)]. MicroRNAsmayprovide alternative strategies for intervention. For instance miR-375 that is downregulated in pancreatic cancer can be used as an alternative strategy to counteract the KRAS-PDK1 axis. Interestingly, miR-375 has been found downregulated in multiple types of cancer, and suppresses core hallmarks of cancer by targeting several important oncogenes such as yes-associated protein 1 (YAP1), insulin-like growth factor 1 (IGF1R) and PDK1[[43](#_ENREF_42)]. These oncogenes might play a key role in pancreatic adenocarcinoma progression. For instance, YAP1 has been found overexpressed in pancreatic cancer tissues and might play an important role in pancreatic cancer growth[[48](#_ENREF_45)]. More importantly, IGF1R is emerging as a novel promising new drug targets in pancreatic cancer therapy[[49](#_ENREF_45)]. Therefore, the understanding of the role of the KRAS-PDK1 axis in pancreatic cancer might provide a number of novel therapeutic opportunities for a cancer that urgently needs immediate response to counteract its grim reality.

**ACKNOWLEDGEMENTS**

We thank Dr. Tania Maffucci for critical reading of the manuscript.

**REFERENCES**

1 **Yachida S**, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. *Oncogene* 2013; **32**: 5253-5260 [PMID: 23416985 DOI: 10.1038/onc.2013.29]

2 **Haeno H**, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012; **148**: 362-375 [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060]

3 **Hruban RH**, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. *Clin Cancer Res* 2000; **6**: 2969-2972 [PMID: 10955772]

4 **Hruban RH**, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. *Am J Pathol* 2000; **156**: 1821-1825 [PMID: 10854204 DOI: 10.1016/S0002-9440(10)65054-7]

5 **Morris JP**, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat Rev Cancer* 2010; **10**: 683-695 [PMID: 20814421 DOI: 10.1038/nrc2899]

6 **Hruban RH**, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, Offerhaus GJ. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *Am J Surg Pathol* 2001; **25**: 579-586 [PMID: 11342768]

7 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

8 **Hruban RH**, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. *Am J Pathol* 1993; **143**: 545-554 [PMID: 8342602]

9 **Shibata D**, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, Perucho M, Arnheim N. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. *Cancer Res* 1990; **50**: 1279-1283 [PMID: 2404591]

10 **Agbunag C**, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. *Cancer Res* 2004; **64**: 5659-5663 [PMID: 15313904 DOI: 10.1158/0008-5472.CAN-04-0807]

11 **Campbell PM**, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. *Cancer Res* 2007; **67**: 2098-2106 [PMID: 17332339 DOI: 10.1158/0008-5472.CAN-06-3752]

12 **Rachagani S**, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM, Jain M, Batra SK. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. *Br J Cancer* 2011; **104**: 1038-1048 [PMID: 21364589 DOI: 10.1038/bjc.2011.31]

13 **Pylayeva-Gupta Y**, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. *Nat Rev Cancer* 2011; **11**: 761-774 [PMID: 21993244 DOI: 10.1038/nrc3106]

14 **di Magliano MP**, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. *Gastroenterology* 2013; **144**: 1220-1229 [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071]

15 **Hofmann I**, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. *PLoS One* 2012; **7**: e44146 [PMID: 22952903 DOI: 10.1371/journal.pone.0044146]

16 **Arvanitakis M**, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Devière J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. *Endoscopy* 2004; **36**: 535-542 [PMID: 15202051 DOI: 10.1055/s-2004-814401]

17 **Falasca M**, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. *Anticancer Agents Med Chem* 2011; **11**: 455-463 [PMID: 21521159 DOI: 10.2174/187152011795677382]

18 **Siveke JT**, Crawford HC. KRAS above and beyond - EGFR in pancreatic cancer. *Oncotarget* 2012; **3**: 1262-1263 [PMID: 23174662]

19 **Yuan TL**, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 2008; **27**: 5497-5510 [PMID: 18794884 DOI: 10.1038/onc.2008.245]

20 **Samuels Y**, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. *Cell Cycle* 2004; **3**: 1221-1224 [PMID: 15467468 DOI: 10.4161/cc.3.10.1164]

21 **Zhao L**, Vogt PK. Class I PI3K in oncogenic cellular transformation. *Oncogene* 2008; **27**: 5486-5496 [PMID: 18794883 DOI: 10.1038/onc.2008.244]

22 **Edling CE**, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM, Falasca M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. *Clin Cancer Res* 2010; **16**: 4928-4937 [PMID: 20876794 DOI: 10.1158/1078-0432.CCR-10-1210]

23 **Raimondi C**, Falasca M. Targeting PDK1 in cancer. *Curr Med Chem* 2011; **18**: 2763-2769 [PMID: 21568903]

24 **Cantley LC**, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci U S A* 1999; **96**: 4240-4245 [PMID: 10200246 DOI: 10.1073/pnas.96.8.4240]

25 **Asano T**, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. *Oncogene* 2004; **23**: 8571-8580 [PMID: 15467756 DOI: 10.1038/sj.onc.1207902]

26 **Hill R**, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, Dry S, Wu H. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. *Cancer Res* 2010; **70**: 7114-7124 [PMID: 20807812 DOI: 10.1158/0008-5472.CAN-10-1649]

27 **Schlieman MG**, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. *Br J Cancer* 2003; **89**: 2110-2115 [PMID: 14647146 DOI: 10.1038/sj.bjc.6601396]

28 **Yamamoto S**, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2004; **10**: 2846-2850 [PMID: 15102693 DOI: 10.1158/1078-0432.CCR-02-1441]

29 **Elghazi L**, Weiss AJ, Barker DJ, Callaghan J, Staloch L, Sandgren EP, Gannon M, Adsay VN, Bernal-Mizrachi E. Regulation of pancreas plasticity and malignant transformation by Akt signaling. *Gastroenterology* 2009; **136**: 1091-1103 [PMID: 19121634 DOI: 10.1053/j.gastro.2008.11.043]

30 **Schmid MC**, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. *Cancer Cell* 2011; **19**: 715-727 [PMID: 21665146 DOI: 10.1016/j.ccr.2011.04.016]

31 **Gagliardi PA**, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. *Neoplasia* 2012; **14**: 719-731 [PMID: 22952425]

32 **Eser S**, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, Michalski CW, Schlitter AM, Esposito I, Kind AJ, Rad L, Schnieke AE, Baccarini M, Alessi DR, Rad R, Schmid RM, Schneider G, Saur D. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. *Cancer Cell* 2013; **23**: 406-420 [PMID: 23453624 DOI: 10.1016/j.ccr.2013.01.023]

33 **Engelman JA**, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat Med* 2008; **14**: 1351-1356 [PMID: 19029981 DOI: 10.1038/nm.1890]

34 **Falasca M**, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, Maffucci T. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. *Br J Cancer* 2010; **102**: 104-114 [PMID: 20051961 DOI: 10.1038/sj.bjc.6605408]

35 **Tan J**, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. *Cancer Discov* 2013; **3**: 1156-1171 [PMID: 23887393 DOI: 10.1158/2159-8290.CD-12-0595]

36 **Ischenko I**, Zhi J, Moll UM, Nemajerova A, Petrenko O. Direct reprogramming by oncogenic Ras and Myc. *Proc Natl Acad Sci U S A* 2013; **110**: 3937-3942 [PMID: 23431158]

37 **Wang GM**, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. *Cancer Res* 2013; **73**: 3248-3261 [PMID: 23580570 DOI: 10.1158/0008-5472.CAN-12-1578]

38 **Garcia-Carracedo D**, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. *Clin Cancer Res* 2013; **19**: 6830-6841 [PMID: 24132918 DOI: 10.1158/1078-0432.CCR-13-0624]

39 **Di Leva G**, Garofalo M, Croce CM. MicroRNAs in cancer. *Annu Rev Pathol* 2014; **9**: 287-314 [PMID: 24079833 DOI: 10.1146/annurev.pathol.4.110807.092222]

40 **Khan S**, Ansarullah D, Jaggi M, Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. *Cancer Res* 2013; **73**: 6541-6547 [PMID: 24204026 DOI: 10.1158/0008-5472.CAN-13-1288]

41 **LaConti JJ**, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT, Wellstein A. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. *PLoS One* 2011; **6**: e20687 [PMID: 21738581 DOI: 10.1371/journal.pone.0020687]

42 **Yabushita S**, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, Kawamura S, Uwagawa S, Suzui M, Tsuda H. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. *Pancreas* 2012; **41**: 1013-1018 [PMID: 22513294 DOI: 10.1097/MPA.0b013e31824ac3a5]

43 **Yan JW**, Lin JS, He XX. The emerging role of miR-375 in cancer. *Int J Cancer* 2013; [PMID: 24166096 DOI: 10.1002/ijc.28563]

44 **Pearn L**, Fisher J, Burnett AK, Darley RL. The role of PKC and PDK1 in monocyte lineage specification by Ras. *Blood* 2007; **109**: 4461-4469 [PMID: 17255356 DOI: 10.1182/blood-2006-09-047217]

45 **El Ouaamari A**, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. *Diabetes* 2008; **57**: 2708-2717 [PMID: 18591395 DOI: 10.2337/db07-1614]

46 **Song SD**, Zhou J, Zhou J, Zhao H, Cen JN, Li DC. MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma. *Oncol Lett* 2013; **6**: 953-959 [PMID: 24137444 DOI: 10.3892/ol.2013.1510]

47 **Meuillet EJ**, Moses SA, Lucero-Acuna A, Guzman R, Jeffrey J, and Pagel M. Nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012; 72(8 Suppl): Abstract nr 3752. doi: 1538-7445.AM2012-3752

48 **Diep CH**, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, Von Hoff DD, Han H. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. *PLoS One* 2012; **7**: e32783 [PMID: 22396793 DOI: 10.1371/journal.pone.0032783]

49 **Rieder S**, Michalski CW, Friess H, Kleeff J. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. *Anticancer Agents Med Chem* 2011; **11**: 427-433 [PMID: 21492074]

**P-Reviewers:** Rajdev L,Tan JM  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**